source
- FDA outlines new onshoring incentives and meeting types for generic drug applicants under GDUFA IVThe FDA released its GDUFA IV commitments, indicating that review timelines for generic drug submissions will remain largely consistent through 2032, mirroring the schedule of the previous five yea…
- Definium's oral LSD candidate passes first Phase 3 trial in generalized anxiety disorderDefinium Therapeutics announced that its oral LSD candidate has successfully completed a Phase 3 trial in generalized anxiety disorder. The study met its primary endpoints, marking the first of tw…